Myriad Genetics, Inc. has entered into a Separation Agreement and Release of Claims with Brian Donnelly, the company’s former Chief Commercial Officer. The agreement, dated October 6, 2026, details the terms of Mr. Donnelly’s departure, which became effective on September 21, 2026.
Mr. Donnelly’s employment with Myriad terminated at the close of business on September 21, 2026. Under the terms of the agreement, which is set to become effective on October 14, 2026, Mr. Donnelly will receive a lump sum severance payment of $1,322,294. This payment is contingent upon his compliance with restrictive covenants, including non-solicitation and non-disparagement clauses, as well as a release of claims against the company.
In addition to the cash severance, the agreement accelerates the vesting of Mr. Donnelly’s outstanding equity awards. All time-based equity grants scheduled to vest within two years following the Separation Date are deemed to vest immediately on September 21, 2026. These vesting installments will be distributed over the two-year period. Furthermore, any outstanding equity awards with unsatisfied performance-based conditions will remain outstanding; if the performance targets are met within the two-year window, the awards will vest according to the original schedule.
The filing confirms that the severance and equity considerations are being made pursuant to Mr. Donnelly’s existing Severance and Change of Control Agreement.
